Maxim Group Reaffirms “Hold” Rating for NeuroSense Therapeutics (NASDAQ:NRSN)

Maxim Group restated their hold rating on shares of NeuroSense Therapeutics (NASDAQ:NRSN) in a research note published on Monday morning, MarketBeat Ratings reports.

NeuroSense Therapeutics Stock Performance

Shares of NASDAQ:NRSN opened at $1.14 on Monday. The business has a fifty day moving average of $1.11 and a 200-day moving average of $1.03. The firm has a market cap of $15.58 million, a PE ratio of -1.34 and a beta of 1.38. NeuroSense Therapeutics has a twelve month low of $0.51 and a twelve month high of $2.33.

NeuroSense Therapeutics (NASDAQ:NRSN) last posted its quarterly earnings data on Wednesday, December 18th. The company reported ($0.11) earnings per share for the quarter.

Institutional Investors Weigh In On NeuroSense Therapeutics

An institutional investor recently bought a new position in NeuroSense Therapeutics stock. Armistice Capital LLC purchased a new stake in NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 1,584,000 shares of the company’s stock, valued at approximately $1,774,000. Armistice Capital LLC owned about 11.59% of NeuroSense Therapeutics as of its most recent SEC filing. Institutional investors own 1.04% of the company’s stock.

NeuroSense Therapeutics Company Profile

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease.